Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to -$1.7 million.

  • Champions Oncology's Cash from Operations fell 51307.42% to -$1.7 million in Q4 2025 from the same period last year, while for Oct 2025 it was $6.2 million, marking a year-over-year increase of 32988.55%. This contributed to the annual value of $7.4 million for FY2025, which is 22035.2% up from last year.
  • As of Q4 2025, Champions Oncology's Cash from Operations stood at -$1.7 million, which was down 51307.42% from $600000.0 recorded in Q3 2025.
  • Champions Oncology's Cash from Operations' 5-year high stood at $6.9 million during Q2 2025, with a 5-year trough of -$4.0 million in Q3 2023.
  • Over the past 5 years, Champions Oncology's median Cash from Operations value was $263500.0 (recorded in 2021), while the average stood at $436900.0.
  • As far as peak fluctuations go, Champions Oncology's Cash from Operations soared by 305333.33% in 2022, and later plummeted by 194666.67% in 2023.
  • Champions Oncology's Cash from Operations (Quarter) stood at $1.2 million in 2021, then skyrocketed by 167.59% to $3.3 million in 2022, then plummeted by 82.08% to $589000.0 in 2023, then plummeted by 148.05% to -$283000.0 in 2024, then plummeted by 513.07% to -$1.7 million in 2025.
  • Its last three reported values are -$1.7 million in Q4 2025, $600000.0 for Q3 2025, and $6.9 million during Q2 2025.